To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min "You always want to go out on a ...

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today 2022 manufacturing expansion plans to meet the growing ...

President, CEO, and Co-founder Timothy J. Miller, Ph.D., announces departure John Maslowski, Chief Commercial Officer, to succeed Dr. Miller as President and CEO COLUMBUS, Ohio--(BUSINESS WIRE)--Forge ...

The CEO of a Grove City genetics medicine manufacturer is stepping down from the company he cofounded in 2020. Forge Biologics said chief executive officer Timothy Miller will leave and that John ...

Forge’s FUEL™ platform and cGMP manufacturing services support the production of AAV for Ascidian’s ACDN-01, the most advanced genetic therapy targeting the underlying cause of Stargardt disease ...

Forge Biologics, a member of the Ajinomoto Bio-Pharma Services group, signed an AAV development and manufacturing agreement to help advance Fractyl Health’s Rejuva* pancreatic gene therapy platform ...

WALTHAM, Mass. and COLUMBUS, Ohio, Nov. 13, 2024 /PRNewswire/ -- Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a pipeline of rationally designed adeno-associated virus (AAV ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min "With unwavering conviction, I ...

The MarketWatch News Department was not involved in the creation of this content. -- Designation grants access to enter the Innovative Licensing and Access Pathway (ILAP) -- Five patients treated with ...

Ascidian Therapeutics (“Ascidian”), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the ...